Department of Pediatrics, Division of Nephrology, University of Minnesota, Academic Office Building, 2450 Riverside Ave S AO-201, Minneapolis, MN, 55454, USA.
Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN, USA.
Pediatr Nephrol. 2024 Jan;39(1):261-268. doi: 10.1007/s00467-023-06110-w. Epub 2023 Aug 3.
Dyslipidemia is a modifiable risk factor for cardiovascular disease. The prevalence of dyslipidemia in pKTR (pediatric kidney transplant recipients) under modern immunosuppression remains unknown. We determined the prevalence, risk factors, co-morbidities, and treatment patterns of lipid abnormalities in pediatric kidney transplant recipients on steroid withdrawal immunosuppression.
pKTR (age ≤ 21 years) at a single center on steroid withdrawal immunosuppression underwent lipid screening between January 1, 2020, and September 30, 2022. Continuous and categorical variables were compared using the Wilcoxon rank-sum and chi-square or Fisher's exact tests, respectively. The correlation between total cholesterol and BMI (body mass index) was assessed using Pearson's product-moment correlation, and predictors of lipid abnormalities were evaluated using the multivariable logistic regression.
A total of 96 patients were included, with a median post-transplant time of 2.5 years (IQR: 1.3-5.4). Of the total, 64.6% (n = 62) of patients had a fasting lipid abnormality. We found a significant linear correlation between total cholesterol and BMI (r = 0.38, p = 0.0022). After multivariable adjustment, every 1 ml/min/1.73 m increase in eGFR was associated with a 2% lower odds of a lipid abnormality (OR 0.979, p = 0.026). Obesity, hypertension, and left ventricular hypertrophy were similar between those with and without lipid abnormalities, while insulin-treated diabetes was more prevalent in recipients with lipid abnormalities (12.9% vs. 0%, p = 0.047). Only 36.5% of patients (n = 19) were referred to a dietician and/or lipid specialist; one received statin therapy.
Lipid abnormalities are highly prevalent in pKTR, but therapeutic intervention is infrequent. Calcineurin inhibition without corticosteroids may not be protective; however, higher eGFR is associated with a lower prevalence of lipid abnormalities. A higher resolution version of the Graphical abstract is available as Supplementary information.
血脂异常是心血管疾病的一个可改变的危险因素。在现代免疫抑制下,pKTR(儿科肾移植受者)的血脂异常患病率尚不清楚。我们确定了在停用类固醇免疫抑制下的儿科肾移植受者中脂质异常的患病率、危险因素、合并症和治疗模式。
在单一中心接受停用类固醇免疫抑制的 pKTR(年龄≤21 岁)于 2020 年 1 月 1 日至 2022 年 9 月 30 日期间进行脂质筛查。分别使用 Wilcoxon 秩和检验和卡方检验或 Fisher 精确检验比较连续和分类变量。使用 Pearson 积矩相关评估总胆固醇和 BMI(体重指数)之间的相关性,并使用多变量逻辑回归评估血脂异常的预测因素。
共纳入 96 例患者,中位移植后时间为 2.5 年(IQR:1.3-5.4)。其中,64.6%(n=62)的患者空腹血脂异常。我们发现总胆固醇与 BMI 之间存在显著的线性相关性(r=0.38,p=0.0022)。在多变量调整后,eGFR 每增加 1ml/min/1.73m,血脂异常的可能性就降低 2%(OR 0.979,p=0.026)。肥胖、高血压和左心室肥厚在有和没有血脂异常的患者之间相似,而胰岛素治疗的糖尿病在有血脂异常的患者中更为常见(12.9%vs.0%,p=0.047)。只有 36.5%的患者(n=19)被转介给营养师和/或血脂专家;有一名患者接受了他汀类药物治疗。
脂质异常在 pKTR 中高度普遍,但治疗干预很少。没有皮质类固醇的钙调神经磷酸酶抑制可能没有保护作用;然而,更高的 eGFR 与较低的血脂异常患病率相关。图形摘要的高分辨率版本可在补充资料中获得。